Walter C. Darbonne

8.0k citations

46 papers · 6.1k indexed · 2 hit papers · h-index 26

Hematology top 0.5%
Immunology top 2%
Immunology and Allergy top 1%
Oncology top 1%
- HER2/EGFR in Cancer Research 5
Genetics top 2%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 8
Molecular Biology
- Hedgehog Signaling Pathway Studies 7
- Cell death mechanisms and regulation 4
- PI3K/AKT/mTOR signaling in cancer 3
- Cancer therapeutics and mechanisms 3
Cancer Research
- Cancer Genomics and Diagnostics 6
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6

Co-authors: Frédéric J. de Sauvage Richard Horuk Philip E. Hass C A Hébert E. Luis Patricia LoRusso Charles M. Rudin Jennifer A. Low
Cited by: Hematology Immunology Immunology and Allergy
Journals: Nature (1 paper)Science (2 papers)New England Journal of Medicine (1 paper)
Partner nations: United States France United Kingdom

In The Last Decade

Walter C. Darbonne

43 papers receiving 5.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Walter C. Darbonne

Since Specialization

Citations

This map shows the geographic impact of Walter C. Darbonne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter C. Darbonne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter C. Darbonne more than expected).

Fields of papers citing papers by Walter C. Darbonne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter C. Darbonne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter C. Darbonne. The network helps show where Walter C. Darbonne may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Walter C. Darbonne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Walter C. Darbonne Line = papers co-authored together Walter C. Darbonne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers. Journal of Clinical Oncology ·Lee S. Schwartzberg,David R. Spigel,Ari M. Vanderwalde,Richard Michael Zuniga,Jason C. Hong,Tania Szado,Bongin Yoo,Luke Passler,Yong Wang,Walter C. Darbonne,Davey B. Daniel	2024	0
2	MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR). Journal of Clinical Oncology ·David R. Spigel,Maen Hussein,Richard Zuniga,Daruka Mahadevan,Robert A. Winn,Walter C. Darbonne,Bongin Yoo,Young Tae Kim,Zach Whitehead,Ari M. Vanderwalde	2023	1
3	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors Clinical Cancer Research ·Sara M. Tolaney,T. Khanh,Joseph P. Eder,Patricia LoRusso,Colin D. Weekes,Sarat Chandarlapaty,Ching‐Wei Chang,Shang-Chiung Chen,Denise Nazzal,Eva Schuth,Flávia Brunstein,Montserrat Carrasco‐Triguero,Walter C. Darbonne,Jennifer M. Giltnane,W. Michael Flanagan,S. Renee Commerford,Alexander Ungewickell,Geoffrey I. Shapiro,Shanu Modi	2020	15
4	High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing Journal of Molecular Diagnostics ·Yinghui Guan,Oleg Mayba,Thomas Sandmann,Shan Lu,YounJeong Choi,Walter C. Darbonne,Vincent Lévêque,Lisa Ryner,Eric W. Humke,Nga Wan Rachel Tam,Sundari Sujathasarma,Anna Cheung,Richard Bourgon,Mark R. Lackner,Yulei Wang	2017	18
5	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models Molecular Cancer Therapeutics ·Elizabeth A. Punnoose,Joel Johansson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,A. Young,Michael J. Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,Yue Peng,Jason Oeh,Leslie Lee,Sophie Maïga,Wayne J. Fairbrother,Martine Amiot,Andrew J. Souers,Deepak Sampath	2016	223
6	A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors Annals of Oncology ·Shanu Modi,Joseph P. Eder,Patricia LoRusso,Colin D. Weekes,Sarat Chandarlapaty,Sara M. Tolaney,Jonathan McLaughlin,D. Ross Camidge,Ci Wen Chang,Denise Nazzal,Sui-Ning Chen,Eva Schuth,Flávia Brunstein,Walter C. Darbonne,W. Michael Flanagan,Alexander Ungewickell,Geoffrey I. Shapiro	2016	0
7	Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey Cell Death and Disease ·Christina L. Zuch de Zafra,Avi Ashkenazi,Walter C. Darbonne,Melissa Cheu,Klára Tótpál,Shirley Ortega,Heather Flores,Mark Walker,Bruce Kabakoff,Bert L. Lum,Barbara Mounho-Zamora,Scot A. Marsters,Noël Dybdal	2016	14
8	A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Amita Patnaik,Patricia LoRusso,Wells A. Messersmith,Kyriakos P. Papadopoulos,Lia Gore,Muralidhar Beeram,Vanitha Ramakrishnan,Amy H. Kim,Joseph C. Beyer,L-Y Shih,Walter C. Darbonne,Xin Yan,Ron Yu,Hong Xiang,Rainer K. Brachmann,Colin D. Weekes	2014	61
9	Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) Clinical Cancer Research ·Hirdesh Uppal,Estelle Doudement,Kaushiki Mahapatra,Walter C. Darbonne,Daniela Bumbaca,Ben‐Quan Shen,Xiaoyan Du,Ola M. Saad,Kristin Harden Bowles,Steve Olsen,Gail D. Lewis Phillips,Dylan P. Hartley,Mark X. Sliwkowski,Sandhya Girish,Donna M. Dambach,Vanitha Ramakrishnan	2014	150
10	Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist Drug Metabolism and Disposition ·Harvey Wong,Stephen E. Gould,Nageshwar Budha,Walter C. Darbonne,Edward E. Kadel,Hank La,Bruno Alicke,Jason Halladay,Rebecca J. Erickson,Chia C. Portera,Anthony W. Tolcher,J. Infante,Michael Mamounas,John A. Flygare,Cornelis E. C. A. Hop,Wayne J. Fairbrother	2013	42
11	Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials Pancreatology ·Rebecca Brais,Susan E. Davies,Maria O’Donovan,Ben Simpson,Natalie Cook,Walter C. Darbonne,S. Chilcott,Martijn P. Lolkema,Albrecht Neeße,Michelle Lockley,Pippa Corrie,Duncan I. Jodrell,Raaj Praseedom,Emmanuel Huguet,Asif Jah,Neville V. Jamieson,Frédéric J. de Sauvage,David A. Tuveson,Nicholas Carroll	2012	39
12	Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis Toxicological Sciences ·Harvey Wong,Nageshwar Budha,Kristina West,Elizabeth Blackwood,Joseph A. Ware,Ron Yu,Walter C. Darbonne,Stephen E. Gould,Ronald W. Steigerwalt,Rebecca J. Erickson,Cornelis E. A. C. Hop,Patricia LoRusso,S. Gail Eckhardt,Andrew J. Wagner,Iris T. Chan,Michael Mamounas,John A. Flygare,Wayne J. Fairbrother	2012	13
13	Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models Blood ·Deepak Sampath,Elizabeth A. Punnoose,Erwin R. Boghaert,Lisa D. Belmont,Jun Chen,Franklin Peale,Nguyen Tan,Walter C. Darbonne,Yue Peng,Jason Oeh,Leslie Lee,Wayne J. Fairbrother,Andrew J. Souers,Steve W. Elmore,Joel Johansson	2012	2
14	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors Clinical Cancer Research ·Patricia LoRusso,Charles M. Rudin,Josina C. Reddy,Raoul Tibes,Glen J. Weiss,Mitesh J. Borad,Christine L. Hann,Julie R. Brahmer,Ilsung Chang,Walter C. Darbonne,Richard Graham,Kenn L. Zerivitz,Jennifer A. Low,Daniel D. Von Hoff	2011	420
15	Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis Proceedings of the National Academy of Sciences ·Hua Tian,Christopher A. Callahan,Kelly DuPree,Walter C. Darbonne,Christina P. Ahn,Suzie J. Scales,Frédéric J. de Sauvage	2009	332
16	Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates British Journal of Pharmacology ·Sean K. Kelley,Thomas Gelzleichter,Dong Xie,Wyne P. Lee,Walter C. Darbonne,Ferhan Qureshi,Kim M. Kissler,Ezogelin Oflazoglu,Iqbal S. Grewal	2006	46
17	Experimental histoplasmosis in mice treated with anti-murine interferon-γ antibody and in interferon-γ gene knockout mice Microbes and Infection ·Karl V. Clemons,Walter C. Darbonne,John T. Curnutte,Raymond A. Sobel,David A. Stevens	2000	25
18	Ischemic Stroke Injury Is Reduced in Mice Lacking a Functional NADPH Oxidase Stroke ·Claire E. Walder,Simon P. Green,Walter C. Darbonne,Joanne Mathias,Julie Rae,Mary C. Dinauer,John T. Curnutte,George Thomas	1997	292
19	The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor Biochemistry ·Richard Horuk,Timothy J. Colby,Walter C. Darbonne,Thomas J. Schall,Kuldeep Neote	1993	78
20	Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. Journal of Clinical Investigation ·Walter C. Darbonne,Glenn C. Rice,M Möhler,T Apple,C A Hébert,Anthony J. Valente,J B Baker	1991	372

About Walter C. Darbonne

Walter C. Darbonne is a scholar working on Oncology, Hematology and Cancer Research, having authored 46 papers that have together received 6.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Hedgehog Signaling Pathway Studies (7 papers), Cancer Genomics and Diagnostics (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers), Cell death mechanisms and regulation (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Hematology (1.4k citations), Immunology (1.5k citations) and Immunology and Allergy (437 citations). Walter C. Darbonne has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Frédéric J. de Sauvage, Richard Horuk, Philip E. Hass, C A Hébert, E. Luis, Patricia LoRusso, Charles M. Rudin, Jennifer A. Low, Mitesh J. Borad and Daniel D. Von Hoff. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact